ELAN
resolvedElanco Animal Health Incorporated
Price Chart
Gap Information
Score Analysis
Model 1: Rerate Score
Model 2: Trade Probability
AI Thesis
Elanco's post-earnings gap likely reflects Wall Street's growing conviction that the company has turned a fundamental corner after a prolonged period of post-Bayer-integration indigestion and ZenraQ/seresto-related headwinds. With the Bayer Animal Health integration now largely behind them and deleveraging progressing, investors are likely responding to evidence that Elanco's pet health franchise — particularly its parasiticide portfolio (Credelio, Interceptor Plus) and emerging dermatology pipeline — is driving accelerating organic growth. The companion animal segment tends to carry higher margins and multiple expansion potential, which is critical for re-rating a stock that has traded at a deep discount to pure-play peer Zoetis. The re-rating thesis hinges on Elanco demonstrating that it can sustain mid-to-high single-digit organic revenue growth while expanding gross margins and aggressively paying down debt from the Bayer acquisition. If management raised guidance or backed prior ranges with increased confidence, that signals the worst of the integration disruptions and competitive pressures are behind them. At current levels near $27-28, the stock trades at a meaningful discount to peers, and any confirmation of durable earnings power could attract both value and GARP investors who had avoided the name during its messy post-spin/transformation period.
Analyzed by rerate-v2+glm-5.2 · Aug 5, 2026
Catalysts
- Pet health (companion animal) organic growth accelerating, particularly in parasiticides and dermatology
- Progress on deleveraging — debt paydown from Bayer acquisition improving balance sheet flexibility
- Pipeline advancements in animal health therapeutics including potential landmark launches
- Margin expansion from cost synergy realization and manufacturing optimization post-Bayer integration
- Livestock segment stabilization as cattle cycle and food animal demand recover
Risks
- Significant debt load from Bayer Animal Health acquisition limits financial flexibility and Buyback capacity
- Generic competition on key legacy products pressuring revenue durability
- Volume ratio of 0.67x average suggests the gap may lack conviction — potential for fill if follow-through buying doesn't materialize
- Stock trading above both 50-SMA and 10-EMA — technically extended with potential for near-term pullback
- Livestock segment exposure to commodity cycles and disease outbreaks could offset pet health strength
Technical Setup
Forward Returns
Outcomes calculated Aug 11, 2026
Post-Gap Validation — 5-Day Follow-Through
Day-by-Day Price Action
| Day | Close | High | Low | Volume |
|---|---|---|---|---|
| 📍 Day 1 | $24.20 | $25.35 | $23.60 | 17.21M |
| Day 2 | $22.12 | $24.41 | $22.02 | 22.08M |
| Day 3 | $22.28 | $22.81 | $21.32 | 22.47M |
| Day 4 | Pending | |||
| Day 5 | Pending | |||
Signal Breakdown
Gap 100% filled — price gave back most of the post-earnings gap
Volume sustained — only -31% decline suggests continued accumulation
Lower highs with peak close on day 1 — price action suggests distribution, not accumulation
Drew down 23.1% from gap close — significant give-back
No fundamental data to evaluate beat quality
Analysis updated Aug 11, 2026